Home > News > Detailed Positive ABRAXANE Phase III Data Released
December 8th, 2003
Detailed Positive ABRAXANE Phase III Data Released
American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the CremophorŽ solvent-based TAXOLŽ. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOLŽ.
Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014